These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

160 related articles for article (PubMed ID: 38268755)

  • 1. Levodopa use in Australia: an analysis of Pharmaceutical Benefits Scheme 10% data.
    Evans A; Waterhouse BJ
    BMJ Neurol Open; 2024; 6(1):e000484. PubMed ID: 38268755
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pergolide : A Review of its Pharmacology and Therapeutic Use in Parkinson's Disease.
    Markham A; Benfield P
    CNS Drugs; 1997 Apr; 7(4):328-40. PubMed ID: 27520755
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The XINDI Study: A Randomized Phase III Clinical Trial Evaluating the Efficacy and Safety of Safinamide as Add-On Therapy to Levodopa in Chinese Patients with Parkinson's Disease with Motor Fluctuations.
    Wei Q; Tan Y; Xu P; Tao E; Lu Z; Pan X; Wang B; Liu C; Dong X; Tian Y; Sun X; Cattaneo C; Chen S; Shang H;
    CNS Drugs; 2022 Nov; 36(11):1217-1227. PubMed ID: 36346534
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Safinamide as Add-On Therapy to Levodopa in Mid- to Late-Stage Parkinson's Disease Fluctuating Patients: Post hoc Analyses of Studies 016 and SETTLE.
    Cattaneo C; Sardina M; Bonizzoni E
    J Parkinsons Dis; 2016; 6(1):165-73. PubMed ID: 26889632
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparison of pramipexole versus ropinirole in the treatment of Parkinson's disease.
    Gencler OS; Oztekin N; Oztekin MF
    Ideggyogy Sz; 2022 Jan; 75(1-02):39-49. PubMed ID: 35112520
    [TBL] [Abstract][Full Text] [Related]  

  • 6. COMT Inhibitors in the Management of Parkinson's Disease.
    Fabbri M; Ferreira JJ; Rascol O
    CNS Drugs; 2022 Mar; 36(3):261-282. PubMed ID: 35217995
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Ropinirole: a review of its use in the management of Parkinson's disease.
    Matheson AJ; Spencer CM
    Drugs; 2000 Jul; 60(1):115-37. PubMed ID: 10929932
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Characteristics of levodopa treatment in advanced Parkinson's disease in the experiences of the neurology clinics of Târgu Mureș, Romania].
    Szász JA; Szatmári S; Constantin V; Mihály I; Rácz A; Domokos LC; Vajda T; Orbán-Kis K
    Orv Hetil; 2019 Apr; 160(17):662-669. PubMed ID: 31010306
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prescribing patterns and determinants for elderly patients with Parkinson's disease in Japan: a retrospective observational study using insurance claims databases.
    Seki M; Kawata Y; Hayashi A; Arai M; Fujimoto S
    Front Neurol; 2023; 14():1162016. PubMed ID: 37426443
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Ropinirole for levodopa-induced complications in Parkinson's disease.
    Clarke CE; Deane KH
    Cochrane Database Syst Rev; 2001; (1):CD001516. PubMed ID: 11279718
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Randomized trial of safinamide add-on to levodopa in Parkinson's disease with motor fluctuations.
    Borgohain R; Szasz J; Stanzione P; Meshram C; Bhatt M; Chirilineau D; Stocchi F; Lucini V; Giuliani R; Forrest E; Rice P; Anand R;
    Mov Disord; 2014 Feb; 29(2):229-37. PubMed ID: 24323641
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The modern pre-levodopa era of Parkinson's disease: insights into motor complications from sub-Saharan Africa.
    Cilia R; Akpalu A; Sarfo FS; Cham M; Amboni M; Cereda E; Fabbri M; Adjei P; Akassi J; Bonetti A; Pezzoli G
    Brain; 2014 Oct; 137(Pt 10):2731-42. PubMed ID: 25034897
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The long-acting dopamine receptor agonist cabergoline in early Parkinson's disease: final results of a 5-year, double-blind, levodopa-controlled study.
    Bracco F; Battaglia A; Chouza C; Dupont E; Gershanik O; Marti Masso JF; Montastruc JL;
    CNS Drugs; 2004; 18(11):733-46. PubMed ID: 15330687
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Two-year, randomized, controlled study of safinamide as add-on to levodopa in mid to late Parkinson's disease.
    Borgohain R; Szasz J; Stanzione P; Meshram C; Bhatt MH; Chirilineau D; Stocchi F; Lucini V; Giuliani R; Forrest E; Rice P; Anand R;
    Mov Disord; 2014 Sep; 29(10):1273-80. PubMed ID: 25044402
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Patterns of Daily Motor-Symptom Control with Carbidopa/Levodopa Enteral Suspension Versus Oral Carbidopa/Levodopa Therapy in Advanced Parkinson's Disease: Clinical Trial Post Hoc Analyses.
    Pahwa R; Aldred J; Gupta N; Terasawa E; Garcia-Horton V; Steffen DR; Kandukuri PL; Chaudhari VS; Jalundhwala YJ; Bao Y; Kukreja P; Isaacson SH
    Neurol Ther; 2022 Jun; 11(2):711-723. PubMed ID: 35192177
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Ropinirole for levodopa-induced complications in Parkinson's disease.
    Clarke CE; Deane KH
    Cochrane Database Syst Rev; 2000; (3):CD001516. PubMed ID: 10908503
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The Sydney multicentre study of Parkinson's disease. The first 18 months.
    Hely MA; Morris JG; Rail D; O'Sullivan DJ; Williamson PM; Genge S; Reid WG; Broe GA
    Med J Aust; 1987 Feb; 146(4):195-8. PubMed ID: 3553878
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Evaluation of the efficacy and safety of adjuvant treatment to levodopa therapy in Parkinson s disease patients with motor complications.
    Stowe R; Ives N; Clarke CE; Deane K; ; Wheatley K; Gray R; Handley K; Furmston A
    Cochrane Database Syst Rev; 2010 Jul; (7):CD007166. PubMed ID: 20614454
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Safety and efficacy of continuous subcutaneous foslevodopa-foscarbidopa in patients with advanced Parkinson's disease: a randomised, double-blind, active-controlled, phase 3 trial.
    Soileau MJ; Aldred J; Budur K; Fisseha N; Fung VS; Jeong A; Kimber TE; Klos K; Litvan I; O'Neill D; Robieson WZ; Spindler MA; Standaert DG; Talapala S; Vaou EO; Zheng H; Facheris MF; Hauser RA
    Lancet Neurol; 2022 Dec; 21(12):1099-1109. PubMed ID: 36402160
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Assessment of Treatment Patterns and Patient Outcomes in Levodopa-Induced Dyskinesias (ASTROID): A US Chart Review Study.
    Lennert B; Bibeau W; Farrelly E; Sacco P; Schoor T
    Am Health Drug Benefits; 2012 Sep; 5(6):347-58. PubMed ID: 24991332
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.